Peptomyc

Executive Summary

Peptomyc is a Barcelona-based clinical-stage biotech developing mini-protein therapeutics that directly inhibit MYC, a master regulator of cancer proliferation, survival, and drug resistance. Unlike conventional approaches, its lead candidate OMO-103 targets the MYC transcription factor itself, offering a potentially foundational treatment for a broad range of MYC-driven malignancies. The company has completed a Phase 1 trial demonstrating safety and early signs of efficacy, and is now advancing into Phase 2 studies in multiple solid tumor indications. Peptomyc's technology, spun out from Vall d'Hebron Institute of Oncology, represents one of the most direct and novel strategies to address the long-standing 'undruggable' MYC target, with the potential to complement or replace existing therapies across oncology. With a lean team and a focus on precision medicine, the company is positioned to generate pivotal data over the next 12–18 months that could validate its platform and attract strategic partnerships or additional financing.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout in pancreatic or other solid tumors65% success
• Q2 2027Potential partnership or licensing deal for OMO-103 in specific indications50% success
• Q3 2026Completion of Phase 1 combination study with standard-of-care agents80% success